![]() ![]() The cookie is used to store the user consent for the cookies in the category "Analytics". This cookie is set by GDPR Cookie Consent plugin. These cookies ensure basic functionalities and security features of the website, anonymously. National Institutes of Health, UP cookies are absolutely essential for the website to function properly. The proponents are currently seeking for pharmaceutical companies who will produce, manufacture and distribute the product. Currently, the product is undergoing clinical trials and is at its pre-commercialization stage (TRL 7). The ulasimang-bato drug formulation already has an existing patent for its tablet form. Also, recurrence of hyperuricemia has not been recorded among patients receiving Ulasimang-bato doses. Results of their studies have shown that ulasimang-bato extract has significantly reduced serum uric acid levels and that the percent reduction is comparable with the effects induced by allopurinol. Based on their studies, optimum dosage is recommended initially at 80 mg/kg/day, and then reduced to 40 mg/kg/day after 2 weeks. The proponents have developed a drug formulation from ulasimang-bato extracts that is targeted to cure hyperuricemia and gout. Peperomia pellucida, locally known as “ulasimang-bato” or “pansit-pansitan”, has long been used in Philippine traditional medicine for its analgesic, anti-inflammatory, and anti-hyperuricemic properties. However, despite its efficacy, cases of hyperuricemia recurrence among allopurinol-treated patients are still reported. Allopurinol, a xanthine oxidase inhibitor, is the standard treatment for gouty arthritis and it acts by lowering uric acid levels in the blood. ![]() According to the Philippine Rheumatology Association (PRA), around 1.6M Filipinos are suffering from gout. Gout is the most common type of arthritis among Filipinos. Institute of Herbal Medicine National Institutes of Health, National Integrated Research Program on Medicinal Plants (NIRPROMP), (ulasimang bato) preparation in hyperuricemic patients.You are here: ULASIMANG BATO: Anti-Inflammatory drug formulation | Philippine Council for Health Research and Development ULASIMANG BATO: Anti-Inflammatory drug formulation Technology Generator Phase I Clinical Trial: Comparative efficacy and safety of Peperomia pellucida L. (ampalaya) tablet vs glibenclamide in NIDDM patientsĥ. Phase IV Clinical Trial: Comparative efficacy and safety of Momordica charantia L. ![]() Phase II Confirmatory Clinical Trial: Antispasmodic effect of Carmona retusa (Vhal) Masam (Tsaang gubat) tablets compared with dicycloverine tablets in patients with mild to moderate gastro-intestinal and/or biliary colicĤ. Phase II Multicenter Clinical Trial: Comparative efficacy and safety study of Mentha Cordifolia Opiz (yerba buena) tablets in patients with acute mild to moderate post operative (ipisiotomy, breast biopsy) and dental extraction pain.ģ. ![]() (Lagundi) Syrup vs Placebo among Pediatric Patients with acute cough of moderate severity (Completion-Dec. Phase III Multicenter Clinical Trial of Vitex Negundo L. GENERAL OBJECTIVES: To validate claimed and safety of identified medicinal plant preparations through the conduct of scientific and ethical trials among volunteer subjects with close adherence to the WHO Good Clinical Practice Guidelines.ġ. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |